Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
NEW HAVEN, Conn, Feb. 10, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced the closing of a $70 Million Series 3 equity financing. Current investor, Vatera Healthcare Partners,...
-
NEW HAVEN, Conn, Jan. 9, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced the initiation of a Phase 3 trial of delafloxacin, a novel investigational fluoroquinolone, for the...
-
NEW HAVEN, Conn, Jan. 9, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced that Mary Szela, the Company's chief executive officer, will be providing a corporate and clinical update...
-
NEW HAVEN, Conn, Dec. 2, 2013 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced the appointment of Paul Estrem to the role of chief financial officer. Mr. Estrem brings more than 20 years...
-
NEW HAVEN, Conn, Nov. 19, 2013 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced the appointment of Sue Cammarata, M.D. as chief medical officer. In this role, Dr. Cammarata will be...
-
NEW HAVEN, Conn, Oct. 7, 2013 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced the appointment of Lyn Baranowski as senior vice president, corporate development and strategy. In this...
-
NEW HAVEN, Conn. & NEW YORK, Oct. 7, 2013 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc., formerly Rib-X Pharmaceuticals, today announced the launch a new corporate identity, an...